Patents Represented by Attorney, Agent or Law Firm Valeta Gregg
  • Use of an .alpha.-amylase modified to improve oxidation stability in a combined desizing and bleaching process
    Patent number: 5928381
    Abstract: A process for simultaneously desizing and bleaching of a sized fabric containing starch or starch derivatives, which process comprises treating the fabric with a bleaching composition and an oxidation stable .alpha.-amylase.
    Type: Grant
    Filed: August 22, 1996
    Date of Patent: July 27, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Annette Hanne Toft, Dorthe Marcher, Hanne H.o slashed.st Pedersen, Thomas Erik Nilsson
  • Compounds with growth hormone releasing properties
    Patent number: 5922770
    Abstract: Novel peptide derivatives, compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone are disclosed. The peptides have the formula (I): ##STR1## wherein a, b, A, R.sup.1, L.sup.1, D, R.sup.3, R.sup.4, R.sup.2, L.sup.2, E and G are as defined in the specification. These peptides exhibit improved resistance to proteolytic degradation, and hence, improved bioavailability.
    Type: Grant
    Filed: July 17, 1997
    Date of Patent: July 13, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Bernd Peschke, Michael Ankersen, Thomas Kruse Hansen, Henning Th.o slashed.gersen
  • DNA constructs and methods of producing cellulytic enzymes
    Patent number: 5922586
    Abstract: An isolated nucleic acid constructs encoding cellulytic enzymes derived from a strain of Bacillus agaradherens, recombinant vectors and host cells comprising such constructs, and methods for obtaining cellulytic enzymes.
    Type: Grant
    Filed: September 13, 1996
    Date of Patent: July 13, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Helle Outtrup, Claus Dambmann, Arne Agerlin Olsen, Henrik Bisg.ang.rd-Frantzen, Martin Schulein, Per Linaa Jorgensen, Mads E. Bjoernvad
  • Enzyme with B-1, 3-glucanase activity
    Patent number: 5919688
    Abstract: A DNA construct exhibiting .beta.-1,3-glucanase activity, including an expression vectors, cells harbouring the DNA construct or expression vector, a method of producing the enzyme, as well as the enzyme and preparations containing the enzyme.
    Type: Grant
    Filed: April 14, 1997
    Date of Patent: July 6, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Pau Ferrer, Ivan Diers, Lisbeth Hedegaard, Torben Halkier, Juan A. Asenjo, Demitris Savva
  • Alkaline lipolytic enzyme
    Patent number: 5919746
    Abstract: The present invention relates to an alkaline lipolytic enzyme derivable from a strain of Botryosphaeria or Guignardia, to a lipolytic enzyme-producing microbial strain, to methods for the production of lipolytic enzyme and to a detergent composition comprising the lipolytic enzyme.
    Type: Grant
    Filed: August 28, 1997
    Date of Patent: July 6, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Satoshi Hirayama, Torben Halkier
  • .alpha.-galactosidase enzyme
    Patent number: 5919690
    Abstract: A DNA construct comprising a DNA sequence encoding a polypeptide having .alpha.-galactosidase activity, having the amino acid sequence of SEQ ID NO:3.
    Type: Grant
    Filed: September 12, 1995
    Date of Patent: July 6, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Inge Helmer Knap, Carsten M. Hjort, Torben Halkier, Lene Venke Kofod
  • Enzyme and enzyme preparation with endoglucanase activity
    Patent number: 5919691
    Abstract: DNA sequences are disclosed encoding an enzyme exhibiting endoglucanase activity. The endoglucanase is useful in a variety of industrial processes requiring an alkaline cellulase.
    Type: Grant
    Filed: March 20, 1997
    Date of Patent: July 6, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Martin Schulein, Karen Margrethe Oxenb.o slashed.ll, Lene Nonboe Andersen, S.o slashed.ren Flensted Lassen, Markus Sakari Kauppinen, Jack Bech Nielsen
  • Process for providing localized variation in the color density of fabrics
    Patent number: 5919272
    Abstract: A process for providing improved localised variation in the color density of the surface of dyed fabrics by reducing backstaining, the process including treating a dyed fabric with a cellulytic enzyme in an aqueous liquor and adding a sufficient amount of chelating agent to the liquor to reduce the concentration of di- or trivalent cation to less than 20 mg/l.
    Type: Grant
    Filed: September 18, 1995
    Date of Patent: July 6, 1999
    Assignee: Novo Nordisk A/S
    Inventor: Jack Bech Nielsen
  • Method of obtaining a cellulosic textile fabric with reduced tendency to pilling formation
    Patent number: 5916798
    Abstract: A method for obtaining a cellulosic textile fabric having a strongly reduced tendency to pilling formation, preferably corresponding to a pilling note of at least 4, more preferably of at least 4.5, which method comprises treating the fabric with a cellulase capable of performing a partial hydrolysis of the fibre surface corresponding to a <2% weight loss based on the untreated cellulosic textile fabric. The cellulase is preferably a 43 kD endoglucanase derived from or producible by Humicola insolens, DSM 1800, SEQ ID NO:1, or a functional analogue of said cellulase such as a variant which is modified by substitution of one or more amino acid residues in one or more of the positions 8, 55, 58, 62, 67, 132, 147, 162, 221, 222, 223, 280; or modified by truncation, preferably genetically truncation, at any position from position 213.
    Type: Grant
    Filed: May 8, 1997
    Date of Patent: June 29, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Lund, Hanne H.o slashed.st Pedersen
  • Alkaline cellulases
    Patent number: 5912157
    Abstract: The present invention relates to cellulases derived from the strain Myceliophthora thermophila and variants thereof comprising a core and optionally a C-terminal link consisting of 10 amino acids at the most, especially cellulases having a substrate binding cleft of a depth of at least 12 .ANG., exhibit enhanced enzyme activity in the alkaline pH range while exerting a moderate cellulolytic action on the cellulosic substrate and are, for example, useful in detergent compositions, especially for soil removal or color clarification or preventing backstaining; in fabric softeners; for bio-polishing of textiles; for drainage improvement of paper pulp; for deinking of old paper; for plant degradation.
    Type: Grant
    Filed: September 9, 1996
    Date of Patent: June 15, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Claus von der Osten, Martin Schulein
  • Pyrodictium xylanase, amylase and pullulanase
    Patent number: 5912150
    Abstract: The present invention relates to an amylase from the genus Pyrodictium, specifically to an amylase from Pyrodictium abyssi and more specifically to an amylase from Pyrodictium abyssi, DSM 6158, which has amylase activity optimum at temperatures in the range 110-120.degree. C., determined at pH 5.5 with starch as a substrate.
    Type: Grant
    Filed: May 13, 1997
    Date of Patent: June 15, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Carsten Sj.o slashed.holm, Garabed Antranikian
  • Method for producing powder formulation comprising an insulin
    Patent number: 5898028
    Abstract: A therapeutic powder formulation suitable for pulmonary administration comprising particles composed of human insulin or any analogue or derivative thereof and an enhancer which enhances the absorption of insulin in the lower respiratory tract, wherein at least 50% by weight of the particles are crystalline.
    Type: Grant
    Filed: March 20, 1998
    Date of Patent: April 27, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Steen Jensen, Philip Hansen
  • Crystallization of proteins
    Patent number: 5898067
    Abstract: A method of providing zinc containing crystals of a protein derivative which has a lysine residue which carries a lipophilic substituent on the .epsilon.-amino group, said method comprising providing a solution of the protein derivative in an alkaline buffer, which further contains a zinc salt, adjusting the pH value of the solution to a value between 7 and 10, and isolating the crystals formed.
    Type: Grant
    Filed: February 2, 1998
    Date of Patent: April 27, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Per Balschmidt, Jean Lesley Whittingham
  • Methods for producing polypeptides in respiratory-deficient cells
    Patent number: 5891669
    Abstract: The present invention relates to methods of producing a polypeptide, comprising: (a) introducing into a respiratory-defective mutant of a cell (i) one or more first nucleic acid sequences which complement the respiratory defect and (ii) a second nucleic acid sequence which encodes the polypeptide; (b) cultivating the cell containing the first and second nucleic acid sequences in a culture medium under aerobic conditions suitable for expression of the first and second nucleic acid sequences; and (c) isolating the polypeptide from the cultivation medium of the cell. The present invention also relates to methods for disrupting a gene in a respiratory-deficient mutant cell. The present invention further relates to respiratory-deficient mutant cells and methods for obtaining such mutant cells.
    Type: Grant
    Filed: March 17, 1997
    Date of Patent: April 6, 1999
    Assignees: Novo Nordisk A/S, Novoalle,, Novo Nordisk Biotech
    Inventors: Ejner Bech Jensen, Joel R. Cherry, Susan L. Elrod
  • Alkaline protease from Bacillus sp. ZI315
    Patent number: 5888797
    Abstract: This invention is in the field of detergent proteases obtainable from a strain of a new Bacillus sp. ZI 315. Moreover, the invention is directed towards a process for the preparation of the protease, the use of the protease as detergent enzyme, and detergent compositions comprising the protease of the invention.
    Type: Grant
    Filed: July 7, 1997
    Date of Patent: March 30, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Helle Outtrup, Lars Sparre Conrad
  • Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
    Patent number: 5889002
    Abstract: 1,2,4-Thiadiazine and 1,4-thiazine derivatives represented by the formula ##STR1## wherein A, B, D, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are defined in the description, compositions thereof and methods for preparing the compounds are described. The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinologic system.
    Type: Grant
    Filed: January 17, 1997
    Date of Patent: March 30, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Flemming Elmelund Nielsen, Holger Claus Hansen, John Bondo Hansen, Tina M.o slashed.ller Tagmose
  • Process for the production of secondary metabolites
    Patent number: 5882883
    Abstract: The invention relates to an improved process for the production of a secondary metabolite comprising (i) fermentation of a microorganism capable of producing said secondary metabolite, and (ii) recovering said metabolite in substantially pure form. Said microorganism has been modified in a manner whereby the expression of one or more of the DNA sequences coding for (a) peptide(s), (a) protein(s) or (an) enzyme(s), involved in or interfering with the biosynthetic pathway of said secondary metabolite, is regulated differently from the regulation of said DNA sequence(s) in the original microorganism. Further contemplated is a process for production of said microorganism, a DNA construct, a vector or transformation vehicle, a microorganism capable of producing secondary metabolite and finally a secondary metabolite product.
    Type: Grant
    Filed: March 5, 1997
    Date of Patent: March 16, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Michi Egel-Mitani, Henrik M.o slashed.llgaard, Svend Kaasgaard, Klaus Nyegaard Kristiansen
  • Staphylothermus amylase
    Patent number: 5882906
    Abstract: The present invention relates to an amylase isolated from Staphalothermus marinus, DSM 3639, having a temperature optima of 95.degree.-105.degree. C., determined at pH 5.5 and a pH optima of 4.5 to 5.5, determined at 95.degree. C. The amylase can be employed in the production of sweeteners and ethanol.
    Type: Grant
    Filed: September 9, 1996
    Date of Patent: March 16, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Carsten Sj.o slashed.holm, Garabed Antranikian
  • Enzyme with rhamnogalacturonase activity
    Patent number: 5882911
    Abstract: The present invention relates to DNA sequences encoding a rhamnogalacturonase which comprises(a) the DNA sequence of nucleotides 64-1587 of SEQ ID NO:1;(b) a DNA sequence which hybridizes to the same probe as nucleotides 64-1587 of SEQ ID NO:1 under conditions of presoaking in 5.times.SSC and prehybridizing for 1 hour at -40.degree. C. in a solution of 5.times.SSC, 5.times.Denhardt's solution, 50 mM sodium phosphate, pH 6.8, and 50 mg of denatured sonicated calf thymus DNA, followed by hybridization in the same solution supplemented with 50 .mu.Ci 32-P-dCTP labelled probe for 18 h at -40.degree. C., followed by washing three times in 2.times.SSC, 0.2% SDS at 40.degree. C. for 30 minutes; or(c) a DNA sequence encoding an amino acid sequence having amino acids 20-527 of the sequence of SEQ ID NO;2.
    Type: Grant
    Filed: June 22, 1998
    Date of Patent: March 16, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Lene Venke Kofod, Lene Nonboe Andersen, Henrik Dalb.o slashed.ge, Markus Sakari Kauppinen, Stephan Christgau, Hans Peter Heldt-Hansen, Claus Christophersen, Per Munk Nielsen, Alphons Gerard Joseph Voragen, Hendrik Arie Schols
  • DNA integration by transposition
    Patent number: 5882888
    Abstract: Multicopy strains of gram-positive bacteria carrying multiple copies of a DNA sequence of interest may be constructed by use of a method involving introduction of a DNA construct comprising the DNA sequence of interest into the genome of the recipient cell by transposition and subsequent deletion of a marker gene used for selection of the cells having received the DNA construct by a resolution system. The multicopy strains are preferably free from a gene encoding an undesirable marker such as an antibiotic resistance marker.
    Type: Grant
    Filed: July 17, 1997
    Date of Patent: March 16, 1999
    Assignee: Novo Nordisk A/S
    Inventor: Steen Troels J.o slashed.rgensen